Your browser doesn't support javascript.
loading
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.
Mark, Patrick B; Carrero, Juan J; Matsushita, Kunihiro; Sang, Yingying; Ballew, Shoshana H; Grams, Morgan E; Coresh, Josef; Surapaneni, Aditya; Brunskill, Nigel J; Chalmers, John; Chan, Lili; Chang, Alex R; Chinnadurai, Rajkumar; Chodick, Gabriel; Cirillo, Massimo; de Zeeuw, Dick; Evans, Marie; Garg, Amit X; Gutierrez, Orlando M; Heerspink, Hiddo J L; Heine, Gunnar H; Herrington, William G; Ishigami, Junichi; Kronenberg, Florian; Lee, Jun Young; Levin, Adeera; Major, Rupert W; Marks, Angharad; Nadkarni, Girish N; Naimark, David M J; Nowak, Christoph; Rahman, Mahboob; Sabanayagam, Charumathi; Sarnak, Mark; Sawhney, Simon; Schneider, Markus P; Shalev, Varda; Shin, Jung-Im; Siddiqui, Moneeza K; Stempniewicz, Nikita; Sumida, Keiichi; Valdivielso, José M; van den Brand, Jan; Yee-Moon Wang, Angela; Wheeler, David C; Zhang, Lihua; Visseren, Frank L J; Stengel, Benedicte.
Affiliation
  • Mark PB; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
  • Carrero JJ; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Huddinge, Sweden.
  • Matsushita K; Division of Nephrology, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
  • Sang Y; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Baltimore, MD 21205, USA.
  • Ballew SH; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Baltimore, MD 21205, USA.
  • Grams ME; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Baltimore, MD 21205, USA.
  • Coresh J; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Baltimore, MD 21205, USA.
  • Surapaneni A; Department of Medicine, New York University Grossman School of Medicine, 227 East 30th Street, #825 New York, NY 10016, USA.
  • Brunskill NJ; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Baltimore, MD 21205, USA.
  • Chalmers J; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Baltimore, MD 21205, USA.
  • Chan L; John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
  • Chang AR; Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
  • Chinnadurai R; The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
  • Chodick G; Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Cirillo M; Departments of Nephrology and Population Health Sciences, Geisinger Health, 100 N Academy Ave, Danville, PA 17822, USA.
  • de Zeeuw D; Department of Renal Medicine, Salford Care Organisation, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
  • Evans M; Medical Division, Maccabi Healthcare Services, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Garg AX; Dept. "Scuola Medica Salernitana" University of Salerno Fisciano (SA), Italy.
  • Gutierrez OM; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center, Hanzeplein 1, 9713 GZ, Groningen, Netherlands.
  • Heerspink HJL; Department of Clinical Intervention, and Technology (CLINTEC), Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
  • Heine GH; ICES, London, Ontario, Canada.
  • Herrington WG; Division of Nephrology, Western University, London, Ontario, Canada.
  • Ishigami J; Departments of Epidemiology and Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Kronenberg F; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center, Hanzeplein 1, 9713 GZ, Groningen, Netherlands.
  • Lee JY; Saarland University Medical Center, Internal Medicine IV, Nephrology and Hypertension, Medizinische Klinik IIWilhelm-Epstein-Straße 4 60431 Frankfurt am Main, Germany.
  • Levin A; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health (NDPH), and Clinical Trial Service Unit and Epidemiological Studies Unit, NDPH, University of Oxford, Richard Doll Building Old Road Campus Oxford, Oxfordshire, OX3 7LF, United Kingdom.
  • Major RW; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Baltimore, MD 21205, USA.
  • Marks A; Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria.
  • Nadkarni GN; Transplantation Center, Department of Nephrology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.
  • Naimark DMJ; Division of Nephrology, University of British Columbia, Vancouver, Canada.
  • Nowak C; John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
  • Rahman M; Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
  • Sabanayagam C; Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.
  • Sarnak M; Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Sawhney S; Sunnybrook Hospital, University of Toronto, Rm 3861929 Bayview Ave. Toronto, Ontario M4G 3E8, Canada.
  • Schneider MP; Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
  • Shalev V; Division of Nephrology, Department of Medicine, Case Western Reserve University, Cleveland, OH.
  • Shin JI; Ocular Epidemiology Research Group, Singapore Eye Research Institute, Singapore National Eye Centre, The Academia, 20 College Road, Discovery Tower Level 6, Singapore (169856), Singapore.
  • Siddiqui MK; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower Block, 1E Kent Ridge Road Level 11, Singapore (119228), Singapore.
  • Stempniewicz N; Ophthalmology and Visual Sciences Academic Clinical Program (EYE-ACP), Duke-NUS Medical School, 8 College Road, Singapore (169857), Singapore.
  • Sumida K; Division of Nephrology, Tufts Medical Center, Boston, MA.
  • Valdivielso JM; University of Aberdeen, Aberdeen, United Kingdom.
  • van den Brand J; Department of Nephrology and Hypertension, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Yee-Moon Wang A; Institute for Health and Research and Innovation, Maccabi Healthcare Services and Tel Aviv University, Tel Aviv, Israel.
  • Wheeler DC; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Baltimore, MD 21205, USA.
  • Zhang L; Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom.
  • Visseren FLJ; AMGA (American Medical Group Association), Alexandria, VA.
  • Stengel B; Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN.
Eur Heart J ; 44(13): 1157-1166, 2023 04 01.
Article in En | MEDLINE | ID: mdl-36691956
ABSTRACT

AIMS:

Chronic kidney disease (CKD) increases risk of cardiovascular disease (CVD). Less is known about how CVD associates with future risk of kidney failure with replacement therapy (KFRT). METHODS AND

RESULTS:

The study included 25 903 761 individuals from the CKD Prognosis Consortium with known baseline estimated glomerular filtration rate (eGFR) and evaluated the impact of prevalent and incident coronary heart disease (CHD), stroke, heart failure (HF), and atrial fibrillation (AF) events as time-varying exposures on KFRT outcomes. Mean age was 53 (standard deviation 17) years and mean eGFR was 89 mL/min/1.73 m2, 15% had diabetes and 8.4% had urinary albumin-to-creatinine ratio (ACR) available (median 13 mg/g); 9.5% had prevalent CHD, 3.2% prior stroke, 3.3% HF, and 4.4% prior AF. During follow-up, there were 269 142 CHD, 311 021 stroke, 712 556 HF, and 605 596 AF incident events and 101 044 (0.4%) patients experienced KFRT. Both prevalent and incident CVD were associated with subsequent KFRT with adjusted hazard ratios (HRs) of 3.1 [95% confidence interval (CI) 2.9-3.3], 2.0 (1.9-2.1), 4.5 (4.2-4.9), 2.8 (2.7-3.1) after incident CHD, stroke, HF and AF, respectively. HRs were highest in first 3 months post-CVD incidence declining to baseline after 3 years. Incident HF hospitalizations showed the strongest association with KFRT [HR 46 (95% CI 43-50) within 3 months] after adjustment for other CVD subtype incidence.

CONCLUSION:

Incident CVD events strongly and independently associate with future KFRT risk, most notably after HF, then CHD, stroke, and AF. Optimal strategies for addressing the dramatic risk of KFRT following CVD events are needed.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Renal Insufficiency, Chronic Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Middle aged Language: En Journal: Eur Heart J Year: 2023 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Renal Insufficiency, Chronic Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Middle aged Language: En Journal: Eur Heart J Year: 2023 Type: Article Affiliation country: United kingdom